Category: 5317-33-9piperazines

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5317-33-9,3-(4-Methylpiperazin-1-yl)propan-1-ol,as a common compound, the synthetic route is as follows.

Alternative preparation of 3-(4-methylpiperazin-1-yl)propyl{3-[3-(3,5-difluorophenyl)-6-oxo-6H-pyridazin-1-ylmethyl]phenyl}carbamate 600 mg (2.02 mmol) of bis(trichloromethyl) carbonate and 2.10 ml (15.1 mmol) of triethylamine is added successively to a solution, kept at 0 C., of 1.55 g (4.95 mmol) of 2-(3-aminobenzyl)-6-(3,5-difluorophenyl)-2H-pyridazin-3-one in 20 ml of dichloromethane. 850 mg (5.37 mmol) of 3-(N-methylpiperazine)propan-1-ol is then added, and the reaction mixture is stirred at room temperature for 18 hours. The reaction mixture is partitioned between 1 N NaOH and dichloromethane. The organic phase is dried over sodium sulfate and evaporated. The residue is chromatographed on a silica-gel column with dichloromethane/methanol: 3-(4-methylpiperazin-1-yl)propyl{3-[3-(3,5-difluorophenyl)-6-oxo-6H-pyridazin-1-ylmethyl]phenyl}carbamate as colourless crystals., 5317-33-9

The synthetic route of 5317-33-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MERCK PATENT GESELLSCHAFT MIT BESCHRAeNKTER HAFTUNG; US2011/136819; (2011); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

5317-33-9, 3-(4-Methylpiperazin-1-yl)propan-1-ol is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

5317-33-9, Step b:4.775 g (30 mmol) of 3-(4-methylpiperazin-1-yl)propan-1-ol are dissolved in 20 ml of dioxane, 20 ml of 4 N HCl in dioxane are added, and the mixture is evaporated to dryness. This residue is triturated in MTBE, filtered off with suction and dried. This solid (6.7 g) is suspended in 50 ml of acetonitrile, and 6 g (30 mmol) of trichloromethy choroformate, dissolved in 10 ml of acetonitrile, are added at 0. The mixture is stirred at room temperature for a further 48 h. The reaction mixture is filtered off with suction, washed with acetonitrile and dried, giving a white solid, m.p. 248-250 (decomposition).

The synthetic route of 5317-33-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG; US2011/269756; (2011); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5317-33-9,3-(4-Methylpiperazin-1-yl)propan-1-ol,as a common compound, the synthetic route is as follows.

5317-33-9, EXAMPLE 104; 4-{7-[3-(4-Methyl-piperazin-1-yl)-propoxy]-quinazolin-4-yl}-piperidine-1-carboxylic acid (6-pyrrolidin-1-yl-pyridin-3-yl)-amide; To a solution of 3-(4-methylpiperazin-1-yl)-propan-1-ol (0.22 mmol) in anhydrous THF (2 mL) was added NaH (0.4 mmol) and the mixture was stirred at rt for 5 min. Then, 4-(7-fluoro-quinazolin-4-yl)-piperidine-1-carboxylic acid tert-butyl ester (0.2 mmol), prepared as described in Example 65, was added to it and the mixture was stirred at 60 C. for 2 h. It was then concentrated in vacuo and partitioned between water and DCM. The DCM layer was drawn off, washed with water, brine, dried (anhydrous MgSO4), filtered and concentrated in vacuo. This crude product was then treated with 3M HCl/MeOH (2 mL) and stirred at rt for 2 h and then concentrated in vacuo. A portion of the crude residue (0.05 mmol) was dissolved in a mixture of DCM:MeOH (1:1; 2 mL) and neutralized with excess Et3N (0.3 mmol) and treated with (6-pyrrolidin-1-yl-pyridin-3-yl)-carbamic acid 4-nitrophenyl ester hydrochloride (0.075 mmol), which was prepared from 6-Pyrrolidin-1-yl-pyridin-3-ylamine (WO 2002048152 A2) essentially as described in Example 74a, at rt for 1 h. It was then concentrated in vacuo and the crude product was dissolved in DCM and washed with water thrice, then washed with brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude product was then purified by Preparative TLC (silica gel; DCM:MeOH:NH4OH, 90:9:1) to obtain 10 mg (35%) of the title compound. 1H-NMR (300 MHz, CDCl3): 9.13 (s, 1H), 8.08-7.96 (m, 2H), 7.66-7.60 (m, 1H), 7.34-7.22 (m, 2H), 6.39-6.27 (m, 2H), 4.32-4.14 (m, 4H), 3.74-3.59 (m, 1H), 3.46-3.38 (m, 4H), 3.13 (t, 2H), 2.65-2.50 (m, 10H), 2.37 (s, 3H), 2.22-1.86 (m, 10H). LC/MS (ESI): 559.1 (MH)+.

5317-33-9 3-(4-Methylpiperazin-1-yl)propan-1-ol 79208, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; Baindur, Nand; Gaul, Michael David; Kreutter, Kevin Douglas; Baumann, Christian Andrew; Kim, Alexander J.; Xu, Guozhang; Tuman, Robert W.; Johnson, Dana L.; US2006/281772; (2006); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

5317-33-9, 3-(4-Methylpiperazin-1-yl)propan-1-ol is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

5317-33-9, 2. 500 mg of 3-bromo-5-(1H-pyrazol-4-yl)-pyridine, 850 mg of 3-(N-methylpiperazin)-propan-1-ol and 1.69 g of triphenylphosphine are dissolved in dimethylformamide. 1.28 ml of diisopropylazodicarboxylate is added to the reaction. The mixture is stirred over night at room temperature. For workup the mixture is evaporated and dichloromethane is added. The organic phase is washed with diluted HCl. The acidic aqueous phase is neutralized and extracted with dichloromethane. After drying, filtration and evaporation the product is purified by chromatography in ethyl acetate and methanol. 472 mg of 1-{3-[4-(5-bromo-pyridin-3-yl)-pyrazol-1-yl]-propyl}-4-methyl-piperazine are obtained; HPLC-MS: 1.23 min, [M+H] 366

The synthetic route of 5317-33-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG; Hoelzemann, Guenter; Dorsch, Dieter; Jonczyk, Alfred; Amendt, Christiane; Zenke, Frank; US2013/102608; (2013); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics